Literature DB >> 14500398

Bone marrow contains melanoma-reactive CD8+ effector T cells and, compared with peripheral blood, enriched numbers of melanoma-reactive CD8+ memory T cells.

Anne Letsch1, Ulrich Keilholz, Geraldine Assfalg, Volker Mailänder, Eckhard Thiel, Carmen Scheibenbogen.   

Abstract

Circulating melanoma-specific T cells can be frequently detected in patients with melanoma. Effective T-cell immunity and tumor surveillance, however, requires the presence of specific T cells in tissues populated by tumor cells. The bone marrow (BM) is a compartment frequently harboring micrometastatic tumor cells. Here, we compared directly ex vivo in peripheral blood (PB) and BM frequencies and differentiation phenotypes of T cells reactive with the melanoma-associated antigen tyrosinase and with autologous melanoma cells. Using intracellular cytokine and tetramer staining, we detected tyrosinase- and melanoma-reactive CD3+CD8+ T cells in the BM in similar or enhanced frequencies as in PB. Additional characterization of the differentiation subset using CD45RA and CCR7 revealed the presence of specific effector and memory T cells in the BM in all five patients analyzed. Remarkably, the frequency of tyrosinase- and melanoma-specific memory T cells was significantly increased in BM compared with PB. Thus, the BM may be an important compartment for tumor surveillance harboring a tumor-specific memory T-cell pool in addition to effector T cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14500398

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  The immune microenvironment of myeloma.

Authors:  Kimberly Noonan; Ivan Borrello
Journal:  Cancer Microenviron       Date:  2011-08-25

2.  Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion.

Authors:  Wandi Zhang; Jaewon Choi; Wanyong Zeng; Shelby A Rogers; Edwin P Alyea; James G Rheinwald; Christine M Canning; Vladimir Brusic; Tetsuro Sasada; Ellis L Reinherz; Jerome Ritz; Robert J Soiffer; Catherine J Wu
Journal:  Clin Cancer Res       Date:  2010-05-11       Impact factor: 12.531

3.  Long-term persistence of limited HTLV-I Tax-specific cytotoxic T cell clones in a patient with adult T cell leukemia/lymphoma after allogeneic stem cell transplantation.

Authors:  Yukie Tanaka; Hideki Nakasone; Rie Yamazaki; Hidenori Wada; Yuko Ishihara; Koji Kawamura; Kana Sakamoto; Masahiro Ashizawa; Tomohito Machishima; Miki Sato; Kiriko Terasako; Shun-ichi Kimura; Misato Kikuchi; Shinya Okuda; Shinichi Kako; Junya Kanda; Aki Tanihara; Junji Nishida; Yoshinobu Kanda
Journal:  J Clin Immunol       Date:  2012-07-05       Impact factor: 8.317

4.  Phenotype and functional evaluation of ex vivo generated antigen-specific immune effector cells with potential for therapeutic applications.

Authors:  Shuhong Han; Yuju Huang; Yin Liang; Yuchin Ho; Yichen Wang; Lung-Ji Chang
Journal:  J Hematol Oncol       Date:  2009-08-06       Impact factor: 17.388

5.  5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies.

Authors:  A O Gang; T M Frøsig; M K Brimnes; R Lyngaa; M B Treppendahl; K Grønbæk; I H Dufva; P Thor Straten; S R Hadrup
Journal:  Blood Cancer J       Date:  2014-03-28       Impact factor: 11.037

Review 6.  Bone Marrow T Cells and the Integrated Functions of Recirculating and Tissue-Resident Memory T Cells.

Authors:  Francesca Di Rosa; Thomas Gebhardt
Journal:  Front Immunol       Date:  2016-02-16       Impact factor: 7.561

Review 7.  The Emerging Interplay Between Recirculating and Tissue-Resident Memory T Cells in Cancer Immunity: Lessons Learned From PD-1/PD-L1 Blockade Therapy and Remaining Gaps.

Authors:  Silvia Gitto; Ambra Natalini; Fabrizio Antonangeli; Francesca Di Rosa
Journal:  Front Immunol       Date:  2021-11-16       Impact factor: 7.561

8.  High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow.

Authors:  J Joseph Melenhorst; Phillip Scheinberg; Pratip K Chattopadhyay; Emma Gostick; Kristin Ladell; Mario Roederer; Nancy F Hensel; Daniel C Douek; A John Barrett; David A Price
Journal:  Blood       Date:  2008-11-07       Impact factor: 22.113

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.